Experience with starting tacrolimus postoperatively after transsternal extended thymectomy in patients with myasthenia gravis

References

• Gronseth GS, Barohn RJ. Practice parameter: thymectomy for autoimmune myasthenia gravis (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2000;55:7–15
   PubMed Web of Science ®Google Scholar
• Richman DP, Agius MA. Treatment of autoimmune myasthenia gravis. Neurology 2003;61:1652–61
   PubMed Web of Science ®Google Scholar
• Jaretzki 3rd A, Barohn RJ, Ernstoff RM, et al. Myasthenia gravis: recommendations for clinical research standards [Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America]. Neurology 2000;55: 16–23
   Google Scholar
• Saperstein DS, Barohn RJ. Management of myasthenia gravis. Semin Neurol 2004;24:41–8
   PubMed Web of Science ®Google Scholar
• Sieb JP. Myasthenia gravis: emerging new therapy options. Curr Opin Pharmacol 2005;5:303–7
   PubMed Web of Science ®Google Scholar
• Ponseti JM, Azem J, Fort JM, et al. Long-term results of tacrolimus in cyclosporine- and prednisone-dependent myasthenia gravis. Neurology 2005;64:1641–3
   PubMed Web of Science ®Google Scholar
• Ponseti JM, Azem J, Fort JM, et al. Benefits of FK506 (tacrolimus) for residual, cyclosporin- and prednisone-resistant myasthenia gravis: one-year follow-up of an open-label study. Clin Neurol Neurosurg 2005;107:187–90
   PubMed Web of Science ®Google Scholar
• Masaoka A, Yamakawa Y, Niwa H, et al. Extended thymectomy for myasthenia gravis patients: a 20-year review. Ann Thorac Surg 1996;62:853–9
   PubMed Web of Science ®Google Scholar
• López-Cano M, Ponseti-Bosch JM, Espin-Basany E, et al. Clinical and pathologic predictors of outcome in thymoma-associated myasthenia gravis. Ann Thorac Surg 2003;76:1643–9
   PubMed Web of Science ®Google Scholar
• Masaoka A, Monden Y, Nakahara K, Tanioka T. Follow-up study of thymomas with special reference to their clinical stages. Cancer 1981;48:2485–92
   PubMed Web of Science ®Google Scholar
• Ponseti JM. Miastenia gravis. Manual terapéutico. Barcelona: Springer Verlag; 1995
   Google Scholar
• Shrager JB, Deeb ME, Mick R, et al. Transcervical thymectomy for myasthenia gravis achieves results comparable to thymectomy by sternotomy. Ann Thorac Surg 2002;74:320
   PubMed Web of Science ®Google Scholar
• Budde JM, Morris CD, Gal AA, et al. Predictors of outcome in thymectomy for myasthenia gravis. Ann Thorac Surg 2001;72:197–202
   PubMed Web of Science ®Google Scholar
• Venuta F, Rendina EA, De Giacomo T, et al. Thymectomy for myasthenia gravis: a 27-year experience. Eur J Cardiothorac Surg 1999;15:621–4
   PubMed Web of Science ®Google Scholar
• De Perrot M, Liu J, Bril V, McRae K, et al. Prognostic significance of thymomas in patients with myasthenia gravis. Ann Thorac Surg 2002;74:1658–62
   PubMed Web of Science ®Google Scholar
• Huang CS, Hsu HS, Huang BS, et al. Factors influencing the outcome of transsternal thymectomy for myasthenia gravis. Acta Neurol Scand 2005;112:108–14
   PubMed Web of Science ®Google Scholar
• Mantegazza R, Baggi F, Antozzi C, et al. Myasthenia gravis (MG): epidemiological data and prognostic factors. Ann New York Acad Sci 2003;998:413–23
   PubMed Web of Science ®Google Scholar
• Kondo K, Monden Y. Thymoma and myasthenia gravis: a clinical study of 1089 patients from Japan. Ann Thorac Surg 2005;79:219–24
   PubMed Web of Science ®Google Scholar
• Buckingham JM, Howard Jr FM, Bernatz PE, et al. The value of thymectomy in myasthenia gravis: a computer-assisted matched study. Ann Surg 1976;184:453–8
   PubMed Web of Science ®Google Scholar
• DeFilippi VJ, Richman DP, Ferguson MK. Transcervical thymectomy for myasthenia gravis. Ann Thorac Surg 1994;57:194–7
   PubMed Web of Science ®Google Scholar
• Nieto IP, Robledo JPP, Pajuelo MC, et al. Prognostic factors for myasthenia gravis treated by thymectomy: review of 61 cases. Ann Thorac Surg 1999;67:1568–71
   PubMed Web of Science ®Google Scholar
• Stern LE, Nussbaum MS, Quinlan JG, Fischer JE. Long-term evaluation of extended thymectomy with anterior mediastinal dissection for myasthenia gravis. Surgery 2001;130:774–8
   PubMed Web of Science ®Google Scholar
• Ashour M. Prevalence of ectopic thymic tissue in myasthenia gravis and its clinical significance. J Thorac Cardiovasc Surg 1995;109:632–5
   PubMed Web of Science ®Google Scholar
• Ozdemir N, Kara M, Dikmen E, et al. Predictors of clinical outcome following extended thymectomy in myasthenia gravis. Eur J Cardiothorac Surg 2003;23:233–7
   PubMed Web of Science ®Google Scholar
• Zielinski M, Kuzdzal J, Szlubowski A, Soja J. Comparison of late results of basic transsternal and extended transsternal thymectomies in the treatment of myasthenia gravis. Ann Thorac Surg 2004;78:253–8
   PubMed Web of Science ®Google Scholar
• Zielinski M, Kuzdzal J, Szlubowski A, Soja J. Transcervicalsubxiphoid-videothoracoscopic ‘maximal’ thymectomy – operative technique and early results. Ann Thorac Surg 2004;78:404–9
   PubMed Web of Science ®Google Scholar
• De Perrot M, Bril V, McRae K, Keshavjee S. Impact of minimally invasive trans-cervical thymectomy on outcome in patients with myasthenia gravis. Eur J Cardiothorac Surg 2003;24:677–83
   PubMed Web of Science ®Google Scholar
• Drachman DB, Jones RJ, Brodsky RA. Treatment of refractory myasthenia: ‘rebooting’ with high-dose cyclosphosphamide. Ann Neurol 2003;53:29–34
   Google Scholar
• Chaudhry V, Cornblath DR, Griffin JW, et al. Mycophenolate mofetil: a safe and promising immunosuppressant in neuro-muscular diseases. Neurology 2001;56:94–6
   PubMed Web of Science ®Google Scholar
• Ciafaloni E, Massey JM, Tucker-Lipscomb B, Sanders DB. Mycophenolate mofetil for myasthenia gravis: an open-label pilot study. Neurology 2001;56:97–9
   Google Scholar
• Meriggioli MN, Ciafaloni E, Al-Hayk KA, et al. Mycophenolate mofetil for myasthenia gravis. An analysis of efficacy, safety, and tolerability. Neurology 2003;61:1438–40
   Google Scholar
• Zaja F, Russo D, Fuga G, et al. Rituximab for myasthenia gravis developing after bone marrow transplant. Neurology 2000;55:1062–3
   PubMed Web of Science ®Google Scholar
• Rowin J, Meriggioli MN, Tüzün E, et al. Etanercept treatment in corticosteroid-dependent myasthenia gravis. Neurology 2004;63:2390–2
   Google Scholar
• Vidic-Dankovic B, Kosec D, Damjanovic M, et al. Leflunomide prevents the development of experimentally induced myasthenia gravis. Int J Immunopharmacol 1995;17:273–81
   Google Scholar
• Tocci MJ, Sigal NH. Recent advances in the mechanism of action of cyclosporine and FK506. Curr Opin Nephrol Hypertens 1992;1:236–42
   PubMedGoogle Scholar
• Konishi T, Yoshiyama Y, Takamori M, et al.; Japanese FK506 MG Study Group. Clinical study of FK506 in patients with myasthenia gravis. Muscle Nerve 2003;28: 570–4
   Google Scholar
• Wakata N, Saito T, Tanaka S, et al. Tacrolimus hydrate (FK506): therapeutic effects and selection of responders in the treatment of myasthenia gravis. Clin Neurol Neurosurg 2003;106:5–8
   PubMed Web of Science ®Google Scholar
• Kawaguchi N, Yoshiyama Y, Nemoto Y, et al. Low-dose tacrolimus treatment in thymectomised and steroid-dependent myasthenia gravis. Curr Med Res Opin 2004;20:1269–73
   PubMed Web of Science ®Google Scholar
• Tsukaguchi M, Shimamura M, Ikeda K, et al. Low-dose tacrolimus for two cases of myasthenia gravis with invasive thymoma that relapsed shortly after thymectomy. J Neurol Sci 2005;231:85–8
   PubMed Web of Science ®Google Scholar
• Konishi T, Yoshiyama Y, Takamori M, Saida T; the Japanase FK506 MG Study Group. Long-term treatment of generalised myasthenia gravis with FK506 (tacrolimus). J Neurol Neurosurg Psychiatry 2005;76: 448–50
   Google Scholar
• Nagane Y, Utsugisawa K, Obara D, et al. Efficacy of low dose FK506 in the treatment of myasthenia gravis – a randomized pilot study. Eur Neurol 2005;53:146–50
   PubMed Web of Science ®Google Scholar
• Yoshikawa H, Mabuchi K, Yasukawa Y, et al. Low-dose tacrolimus for intractable myasthenia gravis. J Clin Neurosci 2002;9:627–8
   PubMed Web of Science ®Google Scholar
• Marks AR. Cellular functions of immunophilins. Physiol Rev 1996;76:631–49
   PubMed Web of Science ®Google Scholar
• Timerman AP, Ogubumni E, Freund E, et al. The calcium release channel of sarcoplasmic reticulum is modulated by FK-506-binding protein. Dissociation and reconstitution of FKBP-12 to the calcium release channel of skeletal muscle sarcoplasmic reticulum. J Biol Chem 1993;268:22992–9
   Google Scholar
• Sinkins WG, Goel M, Estacion M, Schilling WP. Association of immunophilins with mammalian TRPC channels. J Biol Chem 2004;279:34521–9
   PubMed Web of Science ®Google Scholar
• Takamori M, Motomura M, Kawaguchi N, et al. Anti-ryanodine receptor antibodies and FK506 in myasthenia gravis. Neurology 2004;62:1894–6
   PubMed Web of Science ®Google Scholar
• Davies TH, Ning YM, Sánchez ER. Differential control of glucocorticoid receptor hormone-binding function by tetratricopeptide repeat (TPR) proteins and the immunosuppressive ligand FK506. Biochemistry 2005;44: 2030–8
   Google Scholar
• Vincent A, McConville J, Farrugia ME, Newson-Dawis J. Seronegative myasthenia gravis. Semin Neurol 2004;24:125–33
   PubMed Web of Science ®Google Scholar
• Lauriola L, Ranelletti F, Maggiano N, et al. Thymus changes in anti-MuSK-positive and -negative myasthenia gravis. Neurology 2005;64:536–8
   PubMed Web of Science ®Google Scholar
• Leite MI, Ströbel P, Jones M, et al. Fewer thymic changes in the MuSK antibody-positive than in MuSK antibody-negative MG. Ann Neurol 2005;57:444–8
   PubMed Web of Science ®Google Scholar
• Juel VC. Myasthenia gravis: management of myasthenic crisis and perioperative care. Semin Neurol 2004;24:75–81
   PubMed Web of Science ®Google Scholar
• Watanabe A, Watanabe T, Obama T, et al. Prognostic factors for myasthenic crisis after transsternal thymectomy in patients with myasthenia gravis. J Thorac Cardiovasc Surg 2004;127: 867–76
   Google Scholar
• Szobor A. Crises in myasthenia gravis. New York: Hafner Publishing Company; 1970
   Google Scholar
• Endo S, Hasegawa T, Sato Y, et al. Inhibition of IL-6 overproduction by steroid treatment before transsternal thymectomy for myasthenia gravis: does it help stabilize perioperative condition? Eur J Neurol 2005;12:768–73
   PubMed Web of Science ®Google Scholar
• Takamori M, Ide Y. Effects of prostaglandin E1 in experimental autoimmune myasthenia gravis. Neurology 1982;32:410–3
   PubMed Web of Science ®Google Scholar
• Migita K, Tanaka F, Abiru S, et al. The role of mitochondria in nitric oxide-mediated thymocyte apoptosis. Immunol Lett 2003;90:87–91
   PubMed Web of Science ®Google Scholar
• Kang CB, Feng L, Chia J, Yoon HS. Molecular characterization of FK-506 binding protein 38 and its potential regulatory role on the anti-apoptotic protein Bcl.2. Biochem Biophys Res Commun 2005;337:30–8
   PubMed Web of Science ®Google Scholar
• Migita K, Eguchi K. FK 506-mediated T-cell apoptosis induction. Transplant Proc 2001;33:2292–3
   PubMed Web of Science ®Google Scholar